Free Trial

Brokerages Set TriSalus Life Sciences, Inc. (NASDAQ:TLSI) Target Price at $12.08

TriSalus Life Sciences logo with Medical background

TriSalus Life Sciences, Inc. (NASDAQ:TLSI - Get Free Report) has received an average rating of "Buy" from the eight brokerages that are presently covering the firm, Marketbeat reports. Six research analysts have rated the stock with a buy recommendation and two have issued a strong buy recommendation on the company. The average 1-year price target among brokers that have covered the stock in the last year is $12.08.

Several equities analysts recently weighed in on the stock. Canaccord Genuity Group cut their target price on shares of TriSalus Life Sciences from $12.00 to $11.00 and set a "buy" rating for the company in a research note on Friday, November 15th. Oppenheimer assumed coverage on TriSalus Life Sciences in a research report on Monday, September 16th. They issued an "outperform" rating and a $10.00 target price on the stock. Roth Mkm assumed coverage on TriSalus Life Sciences in a research note on Monday, November 11th. They set a "buy" rating and a $11.00 price target for the company. Roth Capital upgraded TriSalus Life Sciences to a "strong-buy" rating in a research report on Monday, November 11th. Finally, Northland Capmk raised TriSalus Life Sciences to a "strong-buy" rating in a research note on Friday, October 25th.

Check Out Our Latest Analysis on TriSalus Life Sciences

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently modified their holdings of the company. Walleye Capital LLC acquired a new position in shares of TriSalus Life Sciences during the third quarter valued at about $66,000. Virtu Financial LLC acquired a new position in shares of TriSalus Life Sciences in the 3rd quarter valued at $92,000. Vestcor Inc purchased a new stake in shares of TriSalus Life Sciences during the 3rd quarter worth about $108,000. MSD Partners L.P. purchased a new position in TriSalus Life Sciences during the third quarter worth approximately $184,000. Finally, Wolverine Asset Management LLC purchased a new position in shares of TriSalus Life Sciences during the 2nd quarter valued at approximately $240,000. Hedge funds and other institutional investors own 2.58% of the company's stock.

TriSalus Life Sciences Stock Performance

TLSI traded down $0.06 during trading on Friday, reaching $3.91. 19,841 shares of the company traded hands, compared to its average volume of 39,728. The company has a market cap of $119.23 million, a P/E ratio of -1.57 and a beta of 0.56. TriSalus Life Sciences has a 12-month low of $3.50 and a 12-month high of $10.42. The firm has a fifty day simple moving average of $4.19 and a 200 day simple moving average of $5.05.

TriSalus Life Sciences Company Profile

(Get Free Report

TriSalus Life Sciences, Inc, a medical technology company, researches, develops, and sells drug delivery technologies and immune-oncology therapeutics for the treatment of liver and pancreatic cancer. The company offers Pressure Enabled Drug Delivery infusion systems, such as the TriNav infusion system, which is used in transarterial radioembolization and chemoembolization procedures for patients with liver cancer and metastases; and the Pancreatic Retrograde Venous Infusion device, which is in Phase 1 clinical trial, for locally advanced pancreatic cancer.

Further Reading

Analyst Recommendations for TriSalus Life Sciences (NASDAQ:TLSI)

→ Trump’s Secret Manhattan Project (From Banyan Hill Publishing) (Ad)

Should you invest $1,000 in TriSalus Life Sciences right now?

Before you consider TriSalus Life Sciences, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and TriSalus Life Sciences wasn't on the list.

While TriSalus Life Sciences currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

Unlock the Potential in Options Trading Cover

Options trading isn’t just for the Wall Street elite; it’s an accessible strategy for anyone armed with the proper knowledge. Think of options as a strategic toolkit, with each tool designed for a specific financial task. Keep reading to learn how options trading can help you use the market’s volatility to your advantage.

Get This Free Report
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

Broadcom Hits $1 Trillion – Can This AI Powerhouse Go Higher?
SoundHound Stock Explodes Again – Is a Major Breakout Coming?
How Fintech Strategy at FinWise Bancorp and CEO Vision Are Driving 78% Gains

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines